Astral Health & Beauty appoints David Valenzuela as VP of sales for brands CosMedix and Results Rx

ATLANTA , October 19, 2011 (press release) – Astral Health & Beauty today announced the appointment of David Valenzuela to the position of Vice President of Sales for CosMedix and Results Rx. As a seasoned senior executive with a breadth of consumer and professional products experience, business knowledge and industry insight, Mr. Valenzuela will preside over the growth of the beauty innovator's leading cosmeceutical brands.

"CosMedix is poised for growth, and with an executive of David's caliber, we will achieve our potential sooner rather than later," says JuE Wong, Astral Health & Beauty CEO.

Mr. Valenzuela joins Astral Health & Beauty with a proven track record, having propelled both Aveda and Dermalogica to new heights as a senior level executive for both brands. With Mr. Valenzuela's impressive reach and success in multiple distribution channels, CosMedix and Results Rx stand poised for fast-tracked growth and further distribution.

"As Vice President of Sales, my goal is to take full advantage of the solid foundation that the CosMedix/Results Rx team has built and to empower everyone at Astral Health & Beauty to take risks and explore new opportunities," said Mr. Valenzuela. "I believe strong, empowering leaders give their teams the latitude to be successful beyond limitation."

Originally from southern California, Mr. Valenzuela now divides his time between his home state and Atlanta, Georgia.

About Astral Health & Beauty, LLC

Astral Health and Beauty is an innovator in the creation and management of consumer lifestyle brands--Aloette Cosmetics, Pur Minerals and CosMedix--with a business offering that is focused on health and beauty products. The company was established in 1978 and is headquartered in Atlanta, GA.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.